Only slight difference for Delta on effectiveness of Comirnaty

6 October 2021
comirnaty_vaccine_covid_pfizer_big

New research conducted by Pfizer (NYSE: PFE) and published in The Lancet shows effectiveness of the firm’s coronavirus jab waning over time, although not due to the Delta variant of the virus.

In the study, researchers drew from the electronic health records of more than 3.4 million people aged 12 and over in California, USA.

The mRNA-based Comirnaty vaccine, developed together with Germany's BioNTech (Nasdaq: BNTX), was shown to maintain a high level of effectiveness against hospitalization after six months, for all age groups.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology